Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01664039
Other study ID # RDG-11-244
Secondary ID 2012-002078-30
Status Completed
Phase Phase 4
First received August 10, 2012
Last updated July 13, 2015
Start date September 2012
Est. completion date June 2014

Study information

Verified date July 2015
Source Alcon Research
Contact n/a
Is FDA regulated No
Health authority Slovenia: Agency for Medicinal Products - Ministry of HealthSlovenia: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is evaluate effects of TRAVATAN® versus LUMIGAN® on intraocular pressure (IOP) and ocular surface and inflammatory biomarkers.


Recruitment information / eligibility

Status Completed
Enrollment 104
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosed with either open-angle glaucoma or ocular hypertension in at least one eye and be treatment naïve to any glaucoma treatment.

- Intraocular pressure (IOP) between 19 mmHg and 35 mmHg in at least one eye, which would be the study eye.

- IOP considered to be safe (in the opinion of the investigator), in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the study period.

- Able to follow instructions and be willing and able to attend all study visits.

- Best corrected Snellen visual acuity of 6/60 (20/200, 1.0 LogMAR) or better in each eye.

- Must read, sign, and date an Ethics Committee-approved informed consent form.

- Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

- Known medical history of allergy, hypersensitivity or poor tolerance to any components of the study medications to be used in this study that is deemed clinically significant in the opinion of the Principal Investigator.

- Any abnormality preventing reliable applanation tonometry in either eye.

- Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye.

- Prior treatment of dry eye with punctal plugs, punctal cautery, Restasis® or topical ocular corticosteroids.

- History of ocular surface disease (dry eye) or current/prior use of dry eye medications (either over-the counter or prescription medications).

- Contact lens wear.

- Intraocular conventional surgery or laser surgery in either eye that is less than three months prior to the Screening Visit.

- Use of any systemic medications known to affect IOP (e.g., oral beta-adrenergic blockers, alpha-agonists and blockers, angiotensin converting enzyme inhibitors and calcium channel blockers), which have not been on a stable course for at least 7 days prior to Screening Visit or an anticipated change in the dosage during the course of the study.

- Women of childbearing potential not using reliable means of birth control, are pregnant, or lactating.

- Unwilling to risk the possibility of darkened iris or eyelash changes.

- Participation in any other investigational study within 30 days prior to the Screening Visit.

- Other protocol-defined exclusion criteria may apply.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Travoprost 0.004% ophthalmic solution
Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
Bimatoprost 0.01% ophthalmic solution
Ophthalmic solution containing benzalkonium chloride (BAK)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Alcon Research

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change From Baseline in Intraocular Pressure (IOP) at Month 6 IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis. Baseline (Day 0), Month 6 No
Secondary Mean Change From Baseline in IOP at Week 6 and Month 3 IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg. A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis. Baseline (Day 0), Week 6, Month 3 No
Secondary Percentage of Subjects Who Reached Target IOP at Each Visit IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in mmHg. Target IOP was defined as = 18 mmHg. One eye was chosen as the study eye, and only data from the study eye were used for the analysis. Week 6, Month 3, Month 6 No
Secondary Number of Subjects With Change From Baseline in Ocular Hyperaemia by Grade at Each Visit Ocular Hyperaemia (excess of blood in the white of the eyes (sclera)) was graded by the investigator on a 4-point scale where 0=None/Trace, 1=Mild, 2=Moderate, and 3=Severe. One eye was chosen as the study eye, and only data from the study eye were used for the analysis. Baseline (Day 0), Week 6, Month 3, Month 6 No
Secondary Number of Subjects With Change From Baseline in Corneal Staining by Grade at Month 3 and Month 6 Corneal staining was assessed after ophthalmic dye was instilled in the eye. The upper eyelid was lifted slightly, and the eye was compared to grading panels. Corneal staining was graded on a scale from 0 (absent) to 5 (severe). One eye was chosen as the study eye, and only data from the study eye were used for the analysis. Baseline (Day 0), Month 3, Month 6 No
Secondary Number of Subjects With Change From Baseline in Conjunctiva Staining by Grade at Month 3 and Month 6 Conjunctiva staining was assessed after ophthalmic dye was instilled in the eye. The upper eyelid was lifted slightly, and the eye was compared to grading panels. Conjunctiva staining was graded on a scale from 0 (absent) to 5 (severe). One eye was chosen as the study eye, and only data from the study eye were used for the analysis. Baseline (Day 0), Month 3, Month 6 No
Secondary Mean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Month 3 and Month 6 The OSDI questionnaire (used to measure vision-related function, ocular symptoms, visual function, and environmental factors that may affect vision) was answered by the subject. Each of the 12 items was scored on a 0-4 Likert scale, where 0 is "None of the time" and 4 is "All of the time." A resultant overall 0-100 score was calculated, with higher scores representing greater disability. A negative number change represents a perceived improvement in ocular health. Baseline (Day 0), Month 3, Month 6 No
Secondary Mean Change From Baseline In Tear Film Break Up Time (TBUT) at Month 3 and Month 6 TBUT (the time required for dry spots to appear on the corneal surface after blinking) was assessed by the investigator using slit lamp examination . A longer break up time is a sign of a more stable tear film. A positive number change from baseline indicates improvement. One eye was chosen as the study eye, and only data from the study eye were used for the analysis. Baseline (Day 0), Month 3, Month 6 No
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A